ID

19440

Descrizione

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine; ODM derived from: https://clinicaltrials.gov/show/NCT00551538

collegamento

https://clinicaltrials.gov/show/NCT00551538

Keywords

versioni (1)
  1. 02/01/17 02/01/17 -
Caricato su

2 gennaio 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Type 2 Diabetes NCT00551538

Inglese

Eligibility Type 2 Diabetes NCT00551538

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
have type 2 diabetes
Descrizione

Diabetes Mellitus, Non-Insulin-Dependent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011860
have inadequate overall glycemic control (hemoglobin a1c greater than or equal to 7.0% and less than or equal to 12.0%) at or within 4 weeks prior to visit 1
Descrizione

Poor glycemic control | Glucohemoglobin measurement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0342299
UMLS CUI [2]
C0202054
have used:
Descrizione

Use of

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1524063
single or multiple oams for at least 3 months immediately prior to entering the study, including metformin, sulfonylurea, meglitinides (repaglinide, nateglinide), or alpha glucosidase inhibitors (acarbose, miglitol); or
Descrizione

Oral hypoglycemic Single | Oral hypoglycemics multiple | Metformin | Sulfonylurea | Meglitinide | repaglinide | nateglinide | alpha-Glucosidase Inhibitors | Acarbose | miglitol

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0359086
UMLS CUI [1,2]
C0205171
UMLS CUI [2,1]
C0359086
UMLS CUI [2,2]
C0439064
UMLS CUI [3]
C0025598
UMLS CUI [4]
C0038766
UMLS CUI [5]
C0065880
UMLS CUI [6]
C0246689
UMLS CUI [7]
C0903898
UMLS CUI [8]
C1299007
UMLS CUI [9]
C0050393
UMLS CUI [10]
C0066535
insulin (once or twice daily) for at least 3 months immediately prior to entering the study; or
Descrizione

Insulin Once daily | Insulin Twice a day

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021641
UMLS CUI [1,2]
C0556983
UMLS CUI [2,1]
C0021641
UMLS CUI [2,2]
C0585361
a combination of the above.
Descrizione

Combination Pharmaceutical Preparations enumerated

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0205195
UMLS CUI [1,2]
C0013227
UMLS CUI [1,3]
C1707927
are greater than or equal to 21 and less than 80 years of age
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
as determined by the investigator, are capable and willing to:
Descrizione

Capability | Willing

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2698977
UMLS CUI [2]
C0600109
comply with their prescribed diet and medication regimen,
Descrizione

Compliance with prescribed diet | Compliance behavior to prescribed medication

Tipo di dati

boolean

Alias
UMLS CUI [1]
C4039442
UMLS CUI [2]
C2585769
perform self blood glucose monitoring,
Descrizione

Blood Glucose Self-Monitoring

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005803
use the patient diary as required for this protocol,
Descrizione

Study Protocol Subject Diary Use of

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2348563
UMLS CUI [1,2]
C3890583
UMLS CUI [1,3]
C1524063
participate in two 24 hour inpatient assessments
Descrizione

Inpatient Assessment 24 Hours | Participation Assessment Two

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0021562
UMLS CUI [1,2]
C1516048
UMLS CUI [1,3]
C1442770
UMLS CUI [2,1]
C0679823
UMLS CUI [2,2]
C1516048
UMLS CUI [2,3]
C0205448
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
have used a thiazolidinedione (pioglitazone or rosiglitazone) during the 3 months prior to entry into the study
Descrizione

Thiazolidinediones | pioglitazone | rosiglitazone

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2]
C0071097
UMLS CUI [3]
C0289313
are currently treated with a meglitinide without sulfonylurea
Descrizione

Meglitinide | Sulfonylurea

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0065880
UMLS CUI [2]
C0038766
have a known allergy or intolerance to insulin lispro mix 75/25, insulin glargine, or metformin
Descrizione

Hypersensitivity Insulin Lispro Mix 25 75 | Intolerance to Insulin Lispro Mix 25 75 | Hypersensitivity Insulin Glargine | Intolerance to Insulin Glargine | Hypersensitivity Metformin | Intolerance to Metformin

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0977811
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C0977811
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0907402
UMLS CUI [4,1]
C1744706
UMLS CUI [4,2]
C0907402
UMLS CUI [5,1]
C0020517
UMLS CUI [5,2]
C0025598
UMLS CUI [6,1]
C1744706
UMLS CUI [6,2]
C0025598
have plasma creatinine greater than or equal to 1.5 mg/dl (for males) or greater than or equal to 1.4 mg/dl (for females) for patients who will be treated with metformin or; greater than 2 mg/dl for patients treated with other oams, as determined by a local laboratory
Descrizione

plasma creatinine measurement | Gender | Metformin | Oral hypoglycemics

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1278055
UMLS CUI [2]
C0079399
UMLS CUI [3]
C0025598
UMLS CUI [4]
C0359086
have received chronic (lasting longer than 2 weeks), systemic glucocorticoid therapy (excluding topical and inhaled preparations) within 4 weeks immediately prior to visit 1
Descrizione

Systemic Glucocorticoids chronic | Preparations topical | Inhaled drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3540777
UMLS CUI [1,2]
C0205191
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1522168
UMLS CUI [3]
C0556393
Ritorna all'inizio della pagina

Similar models

Eligibility Type 2 Diabetes NCT00551538

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
have type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Poor glycemic control | Glucohemoglobin measurement
Item
have inadequate overall glycemic control (hemoglobin a1c greater than or equal to 7.0% and less than or equal to 12.0%) at or within 4 weeks prior to visit 1
boolean
C0342299 (UMLS CUI [1])
C0202054 (UMLS CUI [2])
Use of
Item
have used:
boolean
C1524063 (UMLS CUI [1])
Oral hypoglycemic Single | Oral hypoglycemics multiple | Metformin | Sulfonylurea | Meglitinide | repaglinide | nateglinide | alpha-Glucosidase Inhibitors | Acarbose | miglitol
Item
single or multiple oams for at least 3 months immediately prior to entering the study, including metformin, sulfonylurea, meglitinides (repaglinide, nateglinide), or alpha glucosidase inhibitors (acarbose, miglitol); or
boolean
C0359086 (UMLS CUI [1,1])
C0205171 (UMLS CUI [1,2])
C0359086 (UMLS CUI [2,1])
C0439064 (UMLS CUI [2,2])
C0025598 (UMLS CUI [3])
C0038766 (UMLS CUI [4])
C0065880 (UMLS CUI [5])
C0246689 (UMLS CUI [6])
C0903898 (UMLS CUI [7])
C1299007 (UMLS CUI [8])
C0050393 (UMLS CUI [9])
C0066535 (UMLS CUI [10])
Insulin Once daily | Insulin Twice a day
Item
insulin (once or twice daily) for at least 3 months immediately prior to entering the study; or
boolean
C0021641 (UMLS CUI [1,1])
C0556983 (UMLS CUI [1,2])
C0021641 (UMLS CUI [2,1])
C0585361 (UMLS CUI [2,2])
Combination Pharmaceutical Preparations enumerated
Item
a combination of the above.
boolean
C0205195 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
C1707927 (UMLS CUI [1,3])
Age
Item
are greater than or equal to 21 and less than 80 years of age
boolean
C0001779 (UMLS CUI [1])
Capability | Willing
Item
as determined by the investigator, are capable and willing to:
boolean
C2698977 (UMLS CUI [1])
C0600109 (UMLS CUI [2])
Compliance with prescribed diet | Compliance behavior to prescribed medication
Item
comply with their prescribed diet and medication regimen,
boolean
C4039442 (UMLS CUI [1])
C2585769 (UMLS CUI [2])
Blood Glucose Self-Monitoring
Item
perform self blood glucose monitoring,
boolean
C0005803 (UMLS CUI [1])
Study Protocol Subject Diary Use of
Item
use the patient diary as required for this protocol,
boolean
C2348563 (UMLS CUI [1,1])
C3890583 (UMLS CUI [1,2])
C1524063 (UMLS CUI [1,3])
Inpatient Assessment 24 Hours | Participation Assessment Two
Item
participate in two 24 hour inpatient assessments
boolean
C0021562 (UMLS CUI [1,1])
C1516048 (UMLS CUI [1,2])
C1442770 (UMLS CUI [1,3])
C0679823 (UMLS CUI [2,1])
C1516048 (UMLS CUI [2,2])
C0205448 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Thiazolidinediones | pioglitazone | rosiglitazone
Item
have used a thiazolidinedione (pioglitazone or rosiglitazone) during the 3 months prior to entry into the study
boolean
C1257987 (UMLS CUI [1])
C0071097 (UMLS CUI [2])
C0289313 (UMLS CUI [3])
Meglitinide | Sulfonylurea
Item
are currently treated with a meglitinide without sulfonylurea
boolean
C0065880 (UMLS CUI [1])
C0038766 (UMLS CUI [2])
Hypersensitivity Insulin Lispro Mix 25 75 | Intolerance to Insulin Lispro Mix 25 75 | Hypersensitivity Insulin Glargine | Intolerance to Insulin Glargine | Hypersensitivity Metformin | Intolerance to Metformin
Item
have a known allergy or intolerance to insulin lispro mix 75/25, insulin glargine, or metformin
boolean
C0020517 (UMLS CUI [1,1])
C0977811 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C0977811 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0907402 (UMLS CUI [3,2])
C1744706 (UMLS CUI [4,1])
C0907402 (UMLS CUI [4,2])
C0020517 (UMLS CUI [5,1])
C0025598 (UMLS CUI [5,2])
C1744706 (UMLS CUI [6,1])
C0025598 (UMLS CUI [6,2])
plasma creatinine measurement | Gender | Metformin | Oral hypoglycemics
Item
have plasma creatinine greater than or equal to 1.5 mg/dl (for males) or greater than or equal to 1.4 mg/dl (for females) for patients who will be treated with metformin or; greater than 2 mg/dl for patients treated with other oams, as determined by a local laboratory
boolean
C1278055 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
C0025598 (UMLS CUI [3])
C0359086 (UMLS CUI [4])
Systemic Glucocorticoids chronic | Preparations topical | Inhaled drugs
Item
have received chronic (lasting longer than 2 weeks), systemic glucocorticoid therapy (excluding topical and inhaled preparations) within 4 weeks immediately prior to visit 1
boolean
C3540777 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C1522168 (UMLS CUI [2,2])
C0556393 (UMLS CUI [3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial